Nasdaq: GTBP

GT Biopharma, Inc.

Immunotherapy for the Treatment of Cancer

Using our proprietary platform technology, GT Biopharma is generating novel immuno-oncology biopharmaceutical drugs targeting cancers such as acute lymphocytic leukemia, non-Hodgkin's lymphoma, acute myeloid leukemia and multiple solid tumors.

View Product Pipeline

GT Biopharma CEO Michael Breen on FDA IND Clearance & Next-Gen Immuno-Oncology

September 2025 Interview with Michael Breen, Executive Chairman and CEO of GT Biopharma

About

GT Biopharma, Inc. (NASDAQ: GTBP) is a clinical stage immuno-oncology company focused on developing innovative therapies based on the Company's proprietary NK cell engager (TriKE®) technology. TriKE® therapeutic agents are targeted immunotherapeutic agents that simultaneously react with natural killer (NK) cells and cancer cells to selectively facilitate the killing of cancer cells.

About

Latest News

GT Biopharma Reports Full Year 2025 Financial Results
Mar 2, 2026 • 7:00 EST | Read More

GT Biopharma to Present at the Centurion One Capital 9th Annual Toronto Growth Conference
Feb 17, 2026 • 7:30 EST | Read More

Investors

GT Biopharma, Inc. Nasdaq: GTBP
Loading... Change
Loading... Volume
Loading... 52 Week Range
Investor Relations Icon
View Our Investor Relations
Click here to sign up for GT Biopharma, Inc. email alerts Email Signup Icon Be first to receive news, events and updates